Advances in diagnosis and treatment of malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive but relatively rare malignancy with median survival ranging from 8 to 14 months depending on stage and presentation of disease. New diagnostic procedures are urgently needed, selecting patients in earlier stages to evaluate therapeutic approaches...
Main Authors: | Giorgio Vittorio Scagliotti, Giovanni Selvaggi |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-12-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/144 |
Similar Items
-
Advances in diagnosis and treatment of malignant pleural mesothelioma
by: Giorgio Vittorio Scagliotti, et al.
Published: (2011-12-01) -
Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis
by: Fawzy M. Amany, et al.
Published: (2013-01-01) -
Combined blood and pleural levels of mesothelin and osteopontin for the diagnosis of malignant pleural mesothelioma
by: Wafaa M. Ashour, et al.
Published: (2012-07-01) -
Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
by: Dannel Yeo, et al.
Published: (2021-08-01) -
Circulating biomarkers in malignant pleural mesothelioma
by: Giuseppe Viscardi, et al.
Published: (2020-12-01)